Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Cutaneous squamous cell carcinoma (cSCC) is a type of non-melanoma skin cancer (NMSC), which is the most frequently diagnosed skin cancer. Most of the cSCCs are localized and easily treatable, and according to the National Center for Biotechnology Information (NCBI), around 5% of patients experience local recurrence, whereas 4% might develop nodal metastases, and around 2% die due to this disease. Increasing incidence of cutaneous squamous-cell carcinoma is expected to boost the market growth. For instance, according to the Journal of the European Academy of Dermatology and Venereology, an article published in January 2019, reports that in the period 2007-2015, 76,474 people newly diagnosed with squamous-cell carcinoma (SCC) were registered in North Rhine?Westphalia (NRW), with an age?standardized incidence in 2015 of 54 in men, double the rate of 26 in women.

The global cutaneous squamous cell carcinoma treatment market is estimated to be valued at US$ 10,309.76 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).

Figure 1. Global Cutaneous Squamous Cell Carcinoma Treatment Market Share (%), by Region, 2020

Cutaneous Squamous Cell Carcinoma Treatment  | Coherent Market Insights

The increasing product development and ongoing trials are expected to propel growth of the global cutaneous squamous cell carcinoma treatment market

Major players in the market are focused on drug development for cutaneous squamous cell carcinoma treatment, which is expected to boost the market growth over the forecast period. for instance, in May 2020, Regeneron Pharmaceuticals, Inc., and Sanofi A.S., collaboratively initiated the clinical trial and announced the longer-term results for Libtayo (cemiplimab-rwlc), PD-1 inhibitor from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (cSCC). The data were presented during the virtual 2020 American Society of Clinical Oncology (ASCO) annual meeting.

request-sample

Cutaneous Squamous Cell Carcinoma Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 10,309.76 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 7.2% 2027 Value Projection: US$ 16,867.06 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment:
    • Surgical: Moh’s Micrographic Surgery (MMS), Electrodessication or Curettage.
    • Non-surgical: Chemotherapy, Topical Immune Response Modifiers, Radiotherapy, Systemic Chemotherapy.
  • By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Others.
Companies covered:

Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc.

Growth Drivers:
  • Rising incidence of cutaneous squamous-cell carcinoma
  • Product development and ongoing trials for the treatment of cutaneous squamous-cell carcinoma
Restraints & Challenges:
  • Lack of standardization in guidelines
  • Longer duration of the surgery and higher cost

Figure 2. Global Cutaneous Squamous Cell Carcinoma Treatment Market Share (%), by Treatment, 2020

Cutaneous Squamous Cell Carcinoma Treatment  | Coherent Market Insights

Increasing approvals for cutaneous squamous cell carcinoma treatment in North America is expected to boost the market growth

North America is expected to hold dominant position in the global cutaneous squamous cell carcinoma treatment market, owing to increasing approvals for cutaneous squamous cell carcinoma treatment in this region. For instance, in June 2020, Merck & Co., Inc., a U.S.-based multinational pharmaceutical company received approval for pembrolizumab (KEYTRUDA) from the U.S. Food and Drug Administration (FDA). The drug is approved for the treatment of recurrent or metastatic cutaneous squamous cell carcinoma (cSCC), which is not curable by surgery or radiation.

Global Cutaneous Squamous Cell Carcinoma Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global Cutaneous Squamous Cell Carcinoma Treatment market during the forecast period.

Key Players

Major players operating in the global Cutaneous Squamous Cell Carcinoma Treatment market include Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others.

Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer grouped in the class of keratinocyte cancer, or non-melanoma skin cancer. It is derived from cells within the epidermis that make keratin, the protein which makes up skin, hair, and nails. Cutaneous squamous cell carcinoma (cSCC) is an invasive disease, referring to cancer cells that have grown beyond the epidermis. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma.

Market Dynamics

Rising incidence of cutaneous squamous cell carcinoma (cSCC) is expected to drive cutaneous squamous-cell carcinoma treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that squamous cell carcinoma is the second most common form of skin cancer in the U.S followed by basal cell carcinoma. It also reports that over one million squamous cell carcinoma cases are diagnosed in the U.S. each year.

However, lack of standardization in the guidelines for cutaneous squamous cell carcinoma (cSCC) creates a challenge for physicians to execute the treatment, and this is expected to hinder the market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that physician's challenge lies in properly assessing a patient's risk for aggressive disease based on tumor or host characteristics.

Key features of the study:

  • This report provides in-depth analysis of the global cutaneous squamous-cell carcinoma treatment  market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global cutaneous squamous-cell carcinoma treatment  market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global cutaneous squamous-cell carcinoma treatment  market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cutaneous squamous-cell carcinoma treatment market.

Detailed Segmentation:

  • Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment:
    • Surgical
      • Moh’s Micrographic Surgery (MMS)
      • Electrodessication or Curettage
    • Non-surgical
      • Chemotherapy
      • Topical Immune Response Modifiers
      • Radiotherapy
      • Systemic Chemotherapy
  • Global Cutaneous Squamous Cell Carcinoma Treatment  Market, By Application:
      • Hospitals
      • Cancer Institutes
      • Ambulatory Surgical Centers
      • Others
  • Global Cutaneous Squamous Cell Carcinoma Treatment  Market, By Region:
    • North America
      • By Treatment:
        • Surgical
          • Moh’s Micrographic Surgery (MMS)
          • Electrodessication or Curettage
        • Non-surgical
          • Chemotherapy
          • Topical Immune Response Modifiers
          • Radiotherapy
          • Systemic Chemotherapy
      • By Application:
        • Hospitals
        • Cancer Institutes
        • Ambulatory Surgical Centers
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Treatment:
        • Surgical
          • Moh’s Micrographic Surgery (MMS)
          • Electrodessication or Curettage
        • Non-surgical
          • Chemotherapy
          • Topical Immune Response Modifiers
          • Radiotherapy
          • Systemic Chemotherapy
      • By Application:
        • Hospitals
        • Cancer Institutes
        • Ambulatory Surgical Centers
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Treatment:
        • Surgical
          • Moh’s Micrographic Surgery (MMS)
          • Electrodessication or Curettage
        • Non-surgical
          • Chemotherapy
          • Topical Immune Response Modifiers
          • Radiotherapy
          • Systemic Chemotherapy
      • By Application:
        • Hospitals
        • Cancer Institutes
        • Ambulatory Surgical Centers
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment:
        • Surgical
          • Moh’s Micrographic Surgery (MMS)
          • Electrodessication or Curettage
        • Non-surgical
          • Chemotherapy
          • Topical Immune Response Modifiers
          • Radiotherapy
          • Systemic Chemotherapy
      • By Application:
        • Hospitals
        • Cancer Institutes
        • Ambulatory Surgical Centers
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment:
        • Surgical
          • Moh’s Micrographic Surgery (MMS)
          • Electrodessication or Curettage
        • Non-surgical
          • Chemotherapy
          • Topical Immune Response Modifiers
          • Radiotherapy
          • Systemic Chemotherapy
      • By Application:
        • Hospitals
        • Cancer Institutes
        • Ambulatory Surgical Centers
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment:
        • Surgical
          • Moh’s Micrographic Surgery (MMS)
          • Electrodessication or Curettage
        • Non-surgical
          • Chemotherapy
          • Topical Immune Response Modifiers
          • Radiotherapy
          • Systemic Chemotherapy
      • By Application:
        • Hospitals
        • Cancer Institutes
        • Ambulatory Surgical Centers
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Eli Lilly and Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Sanofi S.A.
    • Cadila Healthcare Limited.
    • Cipla Limited
    • Castle Biosciences
    • Regeneron Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Vidac Pharma
    • LEO Pharma A/S
    • Regeneron Pharmaceuticals, Inc.
    • Merck Sharp & Dohme
    • Amgen Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Cutaneous Squamous Cell Carcinoma Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Market Scenario
    • Impact of COVID-19 Market on the Cutaneous Squamous-Cell Carcinoma Treatment Products
  5. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Surgical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Moh’s Micrographic Surgery (MMS)
        • Electrodessication or Curettage
      • Non-surgical
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
          • Chemotherapy
          • Topical Immune Response Modifiers
          • Radiotherapy
          • Systemic Chemotherapy
  6. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Cancer Institutes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ambulatory Surgical Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cadila Healthcare Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cipla Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Castle Biosciences
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Regeneron Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Vidac Pharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • LEO Pharma A/S
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Regeneron Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck Sharp & Dohme
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 40 market data tables and 35 figures on "Cutaneous Squamous Cell Carcinoma Treatment Market” - Global forecast to 2027

Frequently Asked Questions

The global cutaneous squamous cell carcinoma treatment market is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).
The global cutaneous squamous cell carcinoma treatment market is estimated to be valued at US$ 10,309.76 million in 2020.
Rising incidence of cutaneous squamous cell carcinoma and ongoing clinical trials for the treatment of cutaneous squamous-cell carcinoma are favoring the market growth.
Non-surgical segment is expected to be the leading treatment segment in the global cutaneous squamous cell carcinoma treatment market during the forecast period (2020-2027).
North America cutaneous squamous cell carcinoma treatment market is expected to generate highest revenue share during the forecast period.
Major players operating in the global cutaneous squamous cell carcinoma treatment market include Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner